Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Immunomedics (IMMU) stocks in Canada

Learn how to easily invest in Immunomedics stocks.

Immunomedics is a biotechnology business based in the US. Immunomedics stocks (IMMU.US) are listed on the NASDAQ and all prices are listed in US Dollars. Immunomedics employs 366 staff and has a trailing 12-month revenue of around $20.4 million.

How to buy shares in Immunomedics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMMU – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Immunomedics stock price (NASDAQ:IMMU)

Use our graph to track the performance of IMMU stocks over time.

Immunomedics shares at a glance

Information last updated 2021-01-22.
52-week range$0.00 - $0.00
50-day moving average $86.42
200-day moving average $49.32
Wall St. target price$75.77
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.63

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Immunomedics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Immunomedics financials

Revenue TTM $20.4 million
Gross profit TTM $-254,576,000
Return on assets TTM -25.16%
Return on equity TTM 0%
Profit margin 0%
Book value $2.57
Market capitalisation $20.3 billion

TTM: trailing 12 months

Immunomedics share dividends

We're not expecting Immunomedics to pay a dividend over the next 12 months.

Have Immunomedics's shares ever split?

Immunomedics's shares were split on a 2:1 basis on 24 June 1985. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Immunomedics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Immunomedics shares which in turn could have impacted Immunomedics's share price.

Immunomedics share price volatility

Over the last 12 months, Immunomedics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immunomedics's is 2.9018. This would suggest that Immunomedics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Immunomedics overview

Immunomedics, Inc. , a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc.

Immunomedics in the news

There are no recent company news

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site